Generic Name: doravirine
Company: Merck & Company
Approval Status: Approved
Generic Version Available: No
Experimental Code: MK-1439
The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents lists Pifeltro plus Descovy (tenofovir alafenamide/emtricitabine) as a recommended initial HIV treatment regimens in certain clinical situations.
Pifeltro is an HIV medication. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Pifeltro was approved by the U.S. Food and Drug Administration for use by people living with HIV in August 2018.
Pifeltro is available as a single drug or as a component of a single-tablet regimen, Delstrigo.
Pifeltro must be used in combination with other HIV drugs.
Adult Dose: One 100mg tablet once a day.
For adults using the antibiotic rifabutin, the dose is one 100mg tablet every 12 hours.
Pediatric Dose: N/A
Dosing Info: Take with or without food.
Common side effects of Pifeltro include nausea, dizziness, headache, fatigue, diarrhea, abdominal pain and abnormal dreams.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Pifeltro or may require dose adjustments, consult the Pifeltro package insert: https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf
Before taking this medication, tell your doctor if you have kidney disease, liver disease (including hepatitis B), or a history of depression/suicidal thoughts. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Last Reviewed: May 21, 2019